Abstract
“Insulin at 100” joins a body of new scholarship being produced globally to commemorate the discovery of insulin. This paper brings to light a new perspective on the collaboration between two North American institutions: the University of Toronto in Canada and Eli Lilly & Company in the United States. It focuses on the collaboration’s complexities, actors who have not been examined previously, and implications for both parties and the general public. The article contributes to existing scholarship by expanding the collaboration story to include central actors at both Eli Lilly and the University of Toronto in a continuous and collaborative cycle of discovery and innovation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
